Prior to joining The Lundquist Institute, Rubayath held the Technology Transfer Manager position at The Rockefeller University in New York where she managed and negotiated Tech Transfer contracts - MTAs, CDAs, and Collaboration Agreements with both industry and academia. She also conducted technology marketing activities and managed compliance with regard to reporting requirements for federal research sponsors.
Rubayath started her Tech Transfer career as a Marketing Analyst Intern at the Johns Hopkins Tech Transfer office and then worked with Columbia Tech Ventures assisting their Marketing Department as a Tech Brief Writer.
Rubayath holds a MSc. in Biotechnology from Johns Hopkins University where she studied radio-sensitizing factors in Glioblastoma cancer stem cells in mouse models. She also earned a BSc. in Biomedical Engineering from Boston University where her research focused on developing a point-of-care sepsis diagnostic chip.
Prior to joining The Lundquist Institute, Angelyn was a Licensing Associate at the Cedars-Sinai Technology Transfer Office where she managed the intellectual property, marketing, and licensing activities for the medical device, software and diagnostics portfolio. She also worked with the legal team to negotiate contracts, including CDAs and IIAs. Before her time at Cedars-Sinai, Angelyn was a Technical Intern at a boutique intellectual property law firm and a Senior Technology Fellow at the UCLA Technology Development Group.
Angelyn earned both her B.S. and Ph.D. in Physiology from UCLA. She worked in the Laboratory of Dr. Amy Rowat studying how the physical properties of pancreatic cancer cells influence cell migration and invasion.
Dr. Hoffman advises the Business Development team regarding commercialization opportunities for The Lundquist Institute's intellectual properties and capabilities.
Prior to The Lundquist Institute, Dr. Hoffman held senior management roles (COO, CBO, VP) in business, corporate, science, and intellectual property development for biotechnology, healthcare data, medical device, and consumer product companies. As part of those efforts Dr. Hoffman drafted, and assisted in the prosecution of, over 70 patents. Most recently, he was part of the founding team at Advera Health Analytics where he developed and helped monetize big data platforms that provide real world side effect data on all FDA approved drugs.
Dr. Hoffman is a native San Diegan who earned both his B.S. in Biology and Ph.D. in Neuroscience from UC Irvine in the laboratory of Dr. Gary Lynch. His research at Irvine focused on the molecular basis of learning and memory with an emphasis on how neural cell adhesion molecules may modulate synaptic architectures.